{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:12:32Z","timestamp":1789708352800,"version":"4.0.1"},"reference-count":118,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foundation of Shanghai Institute of Liver Diseases","award":["10410709400"],"award-info":[{"award-number":["10410709400"]}]},{"name":"Shanghai Science and Technology Commission","award":["10411950100"],"award-info":[{"award-number":["10411950100"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81000968"],"award-info":[{"award-number":["81000968"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81101540"],"award-info":[{"award-number":["81101540"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81101637"],"award-info":[{"award-number":["81101637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172273"],"award-info":[{"award-number":["81172273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272388"],"award-info":[{"award-number":["81272388"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81301820"],"award-info":[{"award-number":["81301820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472673"],"award-info":[{"award-number":["81472673"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctoral Fund of Ministry of Education of China","award":["20120071110058"],"award-info":[{"award-number":["20120071110058"]}]},{"name":"National Clinical Key Special Subject of China"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.canlet.2015.06.023","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T00:50:55Z","timestamp":1437180655000},"page":"245-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["The ubiquitin\u2013proteasome system and its potential application in hepatocellular carcinoma therapy"],"prefix":"10.1016","volume":"379","author":[{"given":"Yan-Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Zhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.06.023_bib0010","article-title":"Global cancer statistics","volume":"2015","author":"Torre","year":"2012","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.canlet.2015.06.023_bib0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.canlet.2015.06.023_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1007117","article-title":"Epidemiology of primary liver cancer","volume":"19","author":"Bosch","year":"1999","journal-title":"Semin. Liver Dis"},{"key":"10.1016\/j.canlet.2015.06.023_bib0025","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1245\/s10434-007-9705-0","article-title":"Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy","volume":"15","author":"Thomas","year":"2008","journal-title":"Ann. Surg. Oncol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2015.03.032","article-title":"Hepatitis C virus core protein induces epithelial-mesenchymal transition in human hepatocytes by upregulating E12\/E47 levels","volume":"362","author":"Tiwari","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2015.06.023_bib0035","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1158\/0008-5472.CAN-14-1211","article-title":"Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer","volume":"74","author":"Pal","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0045","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.2174\/156802611798281320","article-title":"Proteasome structure, function, and lessons learned from beta-lactone inhibitors","volume":"11","author":"Groll","year":"2011","journal-title":"Curr. Top. Med. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1515\/BC.2007.109","article-title":"Diversity of proteasomal missions: fine tuning of the immune response","volume":"388","author":"Borissenko","year":"2007","journal-title":"Biol. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0055","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1074\/jbc.M310265200","article-title":"The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53","volume":"279","author":"Krzywda","year":"2004","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0378-1119(98)00309-6","article-title":"cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome","volume":"216","author":"Hori","year":"1998","journal-title":"Gene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0065","doi-asserted-by":"crossref","first-page":"10893","DOI":"10.1074\/jbc.M107313200","article-title":"Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome","volume":"277","author":"Dawson","year":"2002","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0070","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1107\/S0907444903009892","article-title":"Crystallization of gankyrin, an oncoprotein that interacts with CDK4 and the S6b (rpt3) ATPase of the 19S regulator of the 26S proteasome","volume":"59","author":"Krzywda","year":"2003","journal-title":"Acta Crystallogr. D Biol. Crystallogr"},{"key":"10.1016\/j.canlet.2015.06.023_bib0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/71600","article-title":"Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas","volume":"6","author":"Higashitsuji","year":"2000","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2015.06.023_bib0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.22027","article-title":"Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma","volume":"47","author":"Umemura","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0085","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/srep05503","article-title":"Gradually elevated expression of gankyrin during human hepatocarcinogenesis and its clinicopathological significance","volume":"4","author":"Jing","year":"2014","journal-title":"Sci. Rep"},{"key":"10.1016\/j.canlet.2015.06.023_bib0090","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1021\/bi011550s","article-title":"Novel insights into the INK4-CDK4\/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb","volume":"41","author":"Li","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.canlet.2015.06.023_bib0095","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1038\/onc.2008.43","article-title":"Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells","volume":"27","author":"Qiu","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccr.2005.06.006","article-title":"The oncoprotein gankyrin binds to MDM2\/HDM2, enhancing ubiquitylation and degradation of p53","volume":"8","author":"Higashitsuji","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2015.06.023_bib0105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/cr.2011.103","article-title":"The oncoprotein p28GANK establishes a positive feedback loop in beta-catenin signaling","volume":"21","author":"Dong","year":"2011","journal-title":"Cell Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0110","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1053\/j.gastro.2012.02.042","article-title":"p28(GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis","volume":"142","author":"Qian","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2013.01.093","article-title":"Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (FIH-1) and activating hypoxia-inducible factor-1","volume":"432","author":"Liu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.1016\/j.canlet.2015.06.023_bib0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/hep.24015","article-title":"p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase\/AKT\/hypoxia-inducible factor-1alpha pathways","volume":"53","author":"Fu","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0125","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/hep.24530","article-title":"Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells","volume":"54","author":"Sun","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0130","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bcp.2011.12.034","article-title":"Knockdown of HURP inhibits the proliferation of hepatocellular carcinoma cells via downregulation of gankyrin and accumulation of p53","volume":"83","author":"Kuo","year":"2012","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.27551","article-title":"Interleukin-1beta\/interleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent gankyrin activation during hepatocarcinogenesis","volume":"61","author":"Su","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0140","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1016\/j.cub.2014.02.002","article-title":"Ubiquitin code assembly and disassembly","volume":"24","author":"Heride","year":"2014","journal-title":"Curr. Biol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molcel.2009.01.014","article-title":"Nonproteolytic functions of ubiquitin in cell signaling","volume":"33","author":"Chen","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2015.06.023_bib0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-biochem-093010-153308","article-title":"Ubiquitin-like proteins","volume":"81","author":"van der Veen","year":"2012","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0155","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/sj.onc.1206337","article-title":"Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers","volume":"22","author":"Lee","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0160","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1038\/onc.2008.201","article-title":"Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon","volume":"27","author":"Lukasiak","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0165","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yexmp.2007.12.003","article-title":"Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis","volume":"84","author":"Oliva","year":"2008","journal-title":"Exp. Mol. Pathol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0170","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/onc.2013.236","article-title":"As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt\/GSK3beta pathway","volume":"33","author":"Liu","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.yexmp.2014.01.001","article-title":"Recombinant adenovirus encoding FAT10 small interfering RNA inhibits HCC growth in vitro and in vivo","volume":"96","author":"Chen","year":"2014","journal-title":"Exp. Mol. Pathol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0180","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1158\/0008-5472.CAN-14-0284","article-title":"Ubiquitin-like protein FAT10 promotes the invasion and metastasis of hepatocellular carcinoma by modifying beta-catenin degradation","volume":"74","author":"Yuan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0185","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nature05902","article-title":"Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging","volume":"447","author":"Jin","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2015.06.023_bib0190","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1096\/fj.09-136259","article-title":"The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins","volume":"24","author":"van Wijk","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2015.06.023_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0925-4439(01)00026-6","article-title":"Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas","volume":"1536","author":"Tanaka","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2015.06.023_bib0200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.devcel.2012.08.011","article-title":"Governance of endocytic trafficking and signaling by reversible ubiquitylation","volume":"23","author":"Clague","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2015.06.023_bib0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ccr.2008.06.001","article-title":"The HECT family of E3 ubiquitin ligases: multiple players in cancer development","volume":"14","author":"Bernassola","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2015.06.023_bib0210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ijc.28717","article-title":"The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma","volume":"136","author":"Yin","year":"2015","journal-title":"Int. J. cancer"},{"key":"10.1016\/j.canlet.2015.06.023_bib0215","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1038\/sj.onc.1207101","article-title":"The inhibitors of apoptosis: there is more to life than Bcl2","volume":"22","author":"Liston","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1471-2407-9-125","article-title":"Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma","volume":"9","author":"Augello","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2015.06.023_bib0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00019606-200203000-00007","article-title":"Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma","volume":"11","author":"Ikeguchi","year":"2002","journal-title":"Diagn. Mol. Pathol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0230","first-page":"705","article-title":"Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma","volume":"12","author":"Shiraki","year":"2003","journal-title":"Int. J. Mol. Med"},{"key":"10.1016\/j.canlet.2015.06.023_bib0235","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/sj.onc.1203464","article-title":"Activity of MDM2, a ubiquitin Ligase, toward p53 or itself is dependent on the RING finger domain of the ligase","volume":"19","author":"Honda","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0240","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1034\/j.1600-0676.2000.020003209.x","article-title":"Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma","volume":"20","author":"Endo","year":"2000","journal-title":"Liver"},{"key":"10.1016\/j.canlet.2015.06.023_bib0245","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1007\/s13277-013-1543-z","article-title":"MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis","volume":"35","author":"Chen","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.arcmed.2011.02.002","article-title":"MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis","volume":"42","author":"Liu","year":"2011","journal-title":"Arch. Med. Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0255","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1440-1746.2010.06440.x","article-title":"MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro","volume":"26","author":"Wang","year":"2011","journal-title":"J. Gastroenterol. Hepatol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0260","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/emboj.2011.24","article-title":"Global dissociation of HuR-mRNA complexes promotes cell survival after ionizing radiation","volume":"30","author":"Masuda","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2015.06.023_bib0265","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.24795","article-title":"Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation","volume":"55","author":"Embade","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0270","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1038\/onc.2010.236","article-title":"The role of signaling pathways in the development and treatment of hepatocellular carcinoma","volume":"29","author":"Whittaker","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0275","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1101\/gad.1624008","article-title":"WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase","volume":"22","author":"Hu","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.canlet.2015.06.023_bib0280","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.1162981","article-title":"FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression","volume":"321","author":"Mao","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.06.023_bib0285","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/embor.2009.93","article-title":"REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase","volume":"10","author":"Katiyar","year":"2009","journal-title":"EMBO Rep"},{"key":"10.1016\/j.canlet.2015.06.023_bib0290","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1053\/j.gastro.2009.08.005","article-title":"SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis","volume":"137","author":"Calvisi","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0295","doi-asserted-by":"crossref","first-page":"24058","DOI":"10.1074\/jbc.M603105200","article-title":"Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1","volume":"281","author":"Ji","year":"2006","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0300","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1038\/emm.2014.23","article-title":"Silencing of KIF14 interferes with cell cycle progression and cytokinesis by blocking the p27(Kip1) ubiquitination pathway in hepatocellular carcinoma","volume":"46","author":"Xu","year":"2014","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.canlet.2015.06.023_bib0305","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1158\/1541-7786.MCR-12-0718","article-title":"E.R.K.-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression","volume":"11","author":"Li","year":"2013","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0310","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.molcel.2015.01.015","article-title":"Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress","volume":"57","author":"Lee","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2015.06.023_bib0315","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-2006-960171","article-title":"Genomics and signaling pathways in hepatocellular carcinoma","volume":"27","author":"Villanueva","year":"2007","journal-title":"Semin. Liver Dis"},{"key":"10.1016\/j.canlet.2015.06.023_bib0320","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/gcc.10170","article-title":"SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas","volume":"36","author":"Matsuo","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2015.06.023_bib0325","first-page":"549","article-title":"SIAH1 causes growth arrest and apoptosis in hepatoma cells through beta-catenin degradation-dependent and -independent mechanisms","volume":"17","author":"Yoshibayashi","year":"2007","journal-title":"Oncol. Rep"},{"key":"10.1016\/j.canlet.2015.06.023_bib0330","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.febslet.2011.08.015","article-title":"E3 ubiquitin ligase Siah-1 facilitates poly-ubiquitylation and proteasomal degradation of the hepatitis B viral X protein","volume":"585","author":"Zhao","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.canlet.2015.06.023_bib0335","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2011.02.019","article-title":"Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells","volume":"55","author":"Brauckhoff","year":"2011","journal-title":"J. Hepatol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0340","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/ijc.27473","article-title":"Nuclear accumulation of seven in absentia homologue-2 supports motility and proliferation of liver cancer cells","volume":"131","author":"Malz","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2015.06.023_bib0345","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","article-title":"A genomic and functional inventory of deubiquitinating enzymes","volume":"123","author":"Nijman","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.06.023_bib0350","first-page":"1","article-title":"The potential role of ubiquitin c-terminal hydrolases in oncogenesis","volume":"1806","author":"Fang","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2015.06.023_bib0355","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.febslet.2010.10.042","article-title":"The role of deubiquitinating enzymes in chromatin regulation","volume":"585","author":"Atanassov","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.canlet.2015.06.023_bib0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/carcin\/bgl081","article-title":"Reduced expression of CYLD in human colon and hepatocellular carcinomas","volume":"28","author":"Hellerbrand","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2015.06.023_bib0365","first-page":"121","article-title":"Down-regulation of CYLD as a trigger for NF-kappaB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells","volume":"38","author":"Urbanik","year":"2011","journal-title":"Int. J. Oncol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0370","doi-asserted-by":"crossref","first-page":"e110591","DOI":"10.1371\/journal.pone.0110591","article-title":"Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma","volume":"9","author":"Welte","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.06.023_bib0375","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/carcin\/bgt335","article-title":"CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma","volume":"35","author":"Pannem","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2015.06.023_bib0380","first-page":"559","article-title":"Ubiquitin C-terminal Hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19","volume":"2013","author":"Fang","year":"1833","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2015.06.023_bib0385","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/hep.27682","article-title":"Ubiquitin-specific protease 7 accelerates p14 degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression","volume":"61","author":"Cai","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0390","first-page":"741","article-title":"Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation","volume":"13","author":"Cervello","year":"2004","journal-title":"Int. J. Mol. Med"},{"key":"10.1016\/j.canlet.2015.06.023_bib0395","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.lfs.2009.12.003","article-title":"Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B","volume":"86","author":"Ko","year":"2010","journal-title":"Life Sci"},{"key":"10.1016\/j.canlet.2015.06.023_bib0400","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2407-12-166","article-title":"Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model","volume":"12","author":"Wang","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2015.06.023_bib0405","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.26082","article-title":"Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib","volume":"57","author":"Wahl","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0410","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1002\/cncr.27586","article-title":"Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma","volume":"118","author":"Hui","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2015.06.023_bib0415","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1038\/onc.2010.357","article-title":"CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells","volume":"29","author":"Chen","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.06.023_bib0420","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1158\/0008-5472.CAN-08-0257","article-title":"Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells","volume":"68","author":"Chen","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0425","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jhep.2009.10.011","article-title":"Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation","volume":"52","author":"Chen","year":"2010","journal-title":"J. Hepatol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0430","doi-asserted-by":"crossref","first-page":"e55705","DOI":"10.1371\/journal.pone.0055705","article-title":"Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome","volume":"8","author":"Yu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2015.06.023_bib0435","first-page":"1093","article-title":"Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines","volume":"31","author":"Spratlin","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0440","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biochi.2008.10.015","article-title":"Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels","volume":"91","author":"Baiz","year":"2009","journal-title":"Biochimie"},{"key":"10.1016\/j.canlet.2015.06.023_bib0445","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00535-012-0675-z","article-title":"Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis","volume":"48","author":"Saeki","year":"2013","journal-title":"J. Gastroenterol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0450","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3748\/wjg.v20.i3.795","article-title":"Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines","volume":"20","author":"Baiz","year":"2014","journal-title":"World J. Gastroenterol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0455","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biochi.2015.02.015","article-title":"Impairment of the Pin1\/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells","volume":"112","author":"Farra","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.canlet.2015.06.023_bib0460","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10637-010-9532-1","article-title":"An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma","volume":"30","author":"Kim","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.canlet.2015.06.023_bib0465","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s10637-014-0111-8","article-title":"Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group","volume":"32","author":"Ciombor","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.canlet.2015.06.023_bib0470","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cbi.2014.03.001","article-title":"Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma","volume":"215","author":"Mansour","year":"2014","journal-title":"Chem. Biol. Interact"},{"key":"10.1016\/j.canlet.2015.06.023_bib0475","doi-asserted-by":"crossref","first-page":"10668","DOI":"10.1074\/jbc.M206104200","article-title":"MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity","volume":"278","author":"Nagao","year":"2003","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0480","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1476-4598-12-114","article-title":"LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin\/STAT3\/Akt pathway","volume":"12","author":"Song","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2015.06.023_bib0485","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0490","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0495","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bbamcr.2004.09.025","article-title":"Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach","volume":"1695","author":"Groll","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2015.06.023_bib0505","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Herndon","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0510","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1504\/IJCBDD.2011.044404","article-title":"Discovering a potent small molecule inhibitor for gankyrin using de novo drug design approach","volume":"4","author":"Thakur","year":"2011","journal-title":"Int. J. Comput. Biol. Drug Design"},{"key":"10.1016\/j.canlet.2015.06.023_bib0515","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.06.023_bib0520","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2015.06.023_bib0525","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2011.05.039","article-title":"An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme","volume":"145","author":"Ceccarelli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.06.023_bib0530","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/hep.20203","article-title":"An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice","volume":"39","author":"Pei","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2015.06.023_bib0535","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1200\/JCO.2013.52.3993","article-title":"Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors","volume":"32","author":"Infante","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0540","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2014.06.006","article-title":"Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells","volume":"351","author":"Tian","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2015.06.023_bib0545","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcp.2012.04.023","article-title":"Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells","volume":"84","author":"Chen","year":"2012","journal-title":"Biochem. Pharmacol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0550","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.06.023_bib0555","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Issaeva","year":"2004","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2015.06.023_bib0560","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1021\/jm051122a","article-title":"Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction","volume":"49","author":"Ding","year":"2006","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0565","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1517\/13543780802493366","article-title":"Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer","volume":"17","author":"Patel","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.canlet.2015.06.023_bib0570","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2007-09-112904","article-title":"Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.06.023_bib0575","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.chembiol.2012.09.015","article-title":"Specific small molecule inhibitors of Skp2-mediated p27 degradation","volume":"19","author":"Wu","year":"2012","journal-title":"Chem. Biol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0580","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cellimm.2014.11.003","article-title":"Induction of anti-tumor immunity by dendritic cells transduced with FAT10 recombinant adenovirus in mice","volume":"293","author":"Yang","year":"2015","journal-title":"Cell. Immunol"},{"key":"10.1016\/j.canlet.2015.06.023_bib0585","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1126\/science.1098231","article-title":"A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death","volume":"305","author":"Li","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.06.023_bib0590","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1021\/jm040037k","article-title":"Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer","volume":"47","author":"Oost","year":"2004","journal-title":"J. Med. Chem"},{"key":"10.1016\/j.canlet.2015.06.023_bib0595","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2015.03.001","article-title":"WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation","volume":"361","author":"Liu","year":"2015","journal-title":"Cancer Lett"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515004425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515004425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T18:17:24Z","timestamp":1656353844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515004425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":118,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0304383515004425"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.06.023","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ubiquitin\u2013proteasome system and its potential application in hepatocellular carcinoma therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}